JP2022507065A5 - - Google Patents

Info

Publication number
JP2022507065A5
JP2022507065A5 JP2021525223A JP2021525223A JP2022507065A5 JP 2022507065 A5 JP2022507065 A5 JP 2022507065A5 JP 2021525223 A JP2021525223 A JP 2021525223A JP 2021525223 A JP2021525223 A JP 2021525223A JP 2022507065 A5 JP2022507065 A5 JP 2022507065A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
halo
alkoxy
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021525223A
Other languages
English (en)
Japanese (ja)
Other versions
JP7730759B2 (ja
JP2022507065A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060770 external-priority patent/WO2020102096A1/en
Publication of JP2022507065A publication Critical patent/JP2022507065A/ja
Publication of JP2022507065A5 publication Critical patent/JP2022507065A5/ja
Priority to JP2024091521A priority Critical patent/JP2024113083A/ja
Application granted granted Critical
Publication of JP7730759B2 publication Critical patent/JP7730759B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525223A 2018-11-13 2019-11-11 Nlrp活性に関連する病態を治療するための化合物及び組成物 Active JP7730759B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091521A JP2024113083A (ja) 2018-11-13 2024-06-05 Nlrp活性に関連する病態を治療するための化合物及び組成物

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US201862760209P 2018-11-13 2018-11-13
US201862760244P 2018-11-13 2018-11-13
US201862760248P 2018-11-13 2018-11-13
US62/760,248 2018-11-13
US62/760,209 2018-11-13
US62/760,244 2018-11-13
US201862768811P 2018-11-16 2018-11-16
US62/768,811 2018-11-16
US201862769151P 2018-11-19 2018-11-19
US201862769165P 2018-11-19 2018-11-19
US62/769,165 2018-11-19
US62/769,151 2018-11-19
US201962795919P 2019-01-23 2019-01-23
US62/795,919 2019-01-23
US201962796361P 2019-01-24 2019-01-24
US201962796356P 2019-01-24 2019-01-24
US62/796,361 2019-01-24
US62/796,356 2019-01-24
US201962836585P 2019-04-19 2019-04-19
US201962836577P 2019-04-19 2019-04-19
US201962836575P 2019-04-19 2019-04-19
US62/836,585 2019-04-19
US62/836,575 2019-04-19
US62/836,577 2019-04-19
US201962895595P 2019-09-04 2019-09-04
US62/895,595 2019-09-04
PCT/US2019/060770 WO2020102096A1 (en) 2018-11-13 2019-11-11 Compounds and compositions for treating conditions associated with nlrp activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091521A Division JP2024113083A (ja) 2018-11-13 2024-06-05 Nlrp活性に関連する病態を治療するための化合物及び組成物

Publications (3)

Publication Number Publication Date
JP2022507065A JP2022507065A (ja) 2022-01-18
JP2022507065A5 true JP2022507065A5 (cg-RX-API-DMAC7.html) 2022-11-22
JP7730759B2 JP7730759B2 (ja) 2025-08-28

Family

ID=68841175

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525223A Active JP7730759B2 (ja) 2018-11-13 2019-11-11 Nlrp活性に関連する病態を治療するための化合物及び組成物
JP2024091521A Pending JP2024113083A (ja) 2018-11-13 2024-06-05 Nlrp活性に関連する病態を治療するための化合物及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091521A Pending JP2024113083A (ja) 2018-11-13 2024-06-05 Nlrp活性に関連する病態を治療するための化合物及び組成物

Country Status (32)

Country Link
US (1) US20230031406A1 (cg-RX-API-DMAC7.html)
EP (2) EP4667054A3 (cg-RX-API-DMAC7.html)
JP (2) JP7730759B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210096123A (cg-RX-API-DMAC7.html)
CN (2) CN120531732A (cg-RX-API-DMAC7.html)
AU (1) AU2019379109B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008969A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114918A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001228A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021006075A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210235A (cg-RX-API-DMAC7.html)
DK (1) DK3880660T3 (cg-RX-API-DMAC7.html)
EC (2) ECSP21033236A (cg-RX-API-DMAC7.html)
ES (1) ES3042546T3 (cg-RX-API-DMAC7.html)
FI (1) FI3880660T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251344T1 (cg-RX-API-DMAC7.html)
HU (1) HUE073575T2 (cg-RX-API-DMAC7.html)
IL (1) IL283042B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20210105B1 (cg-RX-API-DMAC7.html)
LT (1) LT3880660T (cg-RX-API-DMAC7.html)
MA (1) MA54229B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005529A (cg-RX-API-DMAC7.html)
MY (1) MY206733A (cg-RX-API-DMAC7.html)
PE (1) PE20211698A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021500025A1 (cg-RX-API-DMAC7.html)
PL (1) PL3880660T3 (cg-RX-API-DMAC7.html)
PT (1) PT3880660T (cg-RX-API-DMAC7.html)
RS (1) RS67257B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202103405TA (cg-RX-API-DMAC7.html)
SI (1) SI3880660T1 (cg-RX-API-DMAC7.html)
TW (1) TWI914296B (cg-RX-API-DMAC7.html)
WO (1) WO2020102096A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649112A1 (en) * 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
CA3158123A1 (en) * 2019-11-12 2021-05-20 Yonggang Wei Amide derivative and preparation method therefore and use thereof in medicine
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
CN117279903A (zh) * 2021-02-10 2023-12-22 杭州英创医药科技有限公司 作为nlrp3抑制剂的化合物
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN116917282B (zh) * 2021-05-10 2026-08-11 康百达(四川)生物医药科技有限公司 酰胺衍生物及其应用
CN116635374B (zh) * 2021-05-10 2025-05-06 康百达(四川)生物医药科技有限公司 酰胺衍生物及其应用
TW202246230A (zh) * 2021-05-10 2022-12-01 大陸商成都百裕製藥股份有限公司 醯胺衍生物及其應用
CN114989058B (zh) * 2022-06-02 2024-04-16 中国科学院成都生物研究所 一种手性氯代砜亚胺类化合物及其衍生物的制备方法
CN115974745B (zh) * 2022-12-27 2025-06-03 瑞石生物医药有限公司 一类含引达省的化合物及其医药用途
CN116253664A (zh) * 2023-02-01 2023-06-13 山东海科创新研究院有限公司 基于双液相微乳化缩合工艺的accp制备方法
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
MA44729A (fr) * 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
US11370763B2 (en) * 2017-07-24 2022-06-28 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
JP7412328B2 (ja) * 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
MA53172A (fr) * 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1

Similar Documents

Publication Publication Date Title
JP2022505525A5 (cg-RX-API-DMAC7.html)
JP2022507506A5 (cg-RX-API-DMAC7.html)
JP7367169B2 (ja) Rip1阻害剤化合物並びにそれを製造及び使用するための方法
JP2022506898A5 (cg-RX-API-DMAC7.html)
JP2020528889A5 (cg-RX-API-DMAC7.html)
ES2796285T3 (es) Indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
ES2981114T3 (es) 8-ciano-5-piperidino-quinolinas como antagonistas de TLR7/8 y sus usos para el tratamiento de trastornos inmunitarios
JP2024521712A5 (cg-RX-API-DMAC7.html)
JP2022507505A5 (cg-RX-API-DMAC7.html)
JP2020537657A5 (cg-RX-API-DMAC7.html)
CN112955438A (zh) 蛋白质酪氨酸磷酸酶抑制剂和其使用方法
JP2022531609A (ja) 新規メチルキナゾリノン誘導体
JP2019515952A5 (cg-RX-API-DMAC7.html)
UA128160C2 (uk) Сполуки, що інгібують rip1, а також способи їх одержання та застосування
JP2019519598A5 (cg-RX-API-DMAC7.html)
JP2019518071A5 (cg-RX-API-DMAC7.html)
JP2021523159A5 (cg-RX-API-DMAC7.html)
TW201629065A (zh) 三唑并嘧啶化合物及其用途
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
UA129653C2 (uk) Макроциклічна сполука як агоніст sting, спосіб з її застосуванням і шлях її застосування
TW202122393A (zh) 吡唑化合物,其配製物以及使用該化合物和/或配製物之方法
TW201938149A (zh) 用於治療癌症的選擇性組蛋白去乙醯酶3 (hdac3)抑制劑及免疫治療劑之組合
JP2022516075A5 (cg-RX-API-DMAC7.html)
WO2021237121A1 (en) Substituted pyridines
WO2024003773A1 (en) 2,7-naphthyridine compounds as mastl inhibitors